Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816104 | 1.00 | KIF11 (0.51) | KIF11DNMT1 | |
| SCHEMBL27558321 | 1.00 | KIF11 (0.51) | KIF11DNMT1 | |
| SCHEMBL2815492 | 0.90 | KIF11 (0.59) | KIF11DNMT1 | |
| SCHEMBL2815491 | 0.90 | KIF11 (0.59) | KIF11DNMT1 | |
| SCHEMBL20202837 | 0.84 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL30408374 | 0.84 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL4410619 | 0.84 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL27452677 | 0.83 | KIF11 (0.45) | KIF11DNMT1 | |
| SCHEMBL4462198 | 0.80 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL4462208 | 0.80 | KIF11 (0.47) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1444194-B1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | CIS BIO INT (FR) | 2009-12-09 | — | — | EP | disclosed |
| CN-1304363-C | N-methyl-homocysteines and their use as well as process for their production | CIS BIOLOGY INTERNAT CO (FR) | 2007-03-14 | — | — | CN | disclosed |
| CN-1589257-A | N-methyl-homocysteine and application and preparation method thereof | SCHERING AG (DE) | 2005-03-02 | — | — | CN | disclosed |
| EP-1444194-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003042163-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | BHMT, BHMT2, AHCY | KIF11 4731/4885DNMT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.